Global Primary Biliary Cirrhosis Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Primary Biliary Cirrhosis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Primary Biliary Cirrhosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 12, 3, 1, 1 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Primary Biliary Cirrhosis - Overview Primary Biliary Cirrhosis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Primary Biliary Cirrhosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development Albireo Pharma Inc Arena Pharmaceuticals Inc Biocad Cadila Healthcare Ltd CymaBay Therapeutics Inc Dr. Falk Pharma GmbH Eisai Co Ltd Enanta Pharmaceuticals Inc Genfit SA GenKyoTex SA Gilead Sciences Inc GlaxoSmithKline Plc Intercept Pharmaceuticals Inc Kowa Co Ltd NGM Biopharmaceuticals Inc Novartis AG Tiziana Life Sciences Plc Virobay Inc For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jqk7tz/global_primary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006123/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 03:42 PM/DISC: 09/25/2018 03:42 PM


Update hourly